Hennion & Walsh Asset Management Inc. Increases Holdings in McKesson Corporation $MCK

Hennion & Walsh Asset Management Inc. boosted its stake in shares of McKesson Corporation (NYSE:MCK) by 16.9% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 11,124 shares of the company’s stock after purchasing an additional 1,611 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in McKesson were worth $8,405,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in McKesson by 46.3% in the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after purchasing an additional 798 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of McKesson during the 1st quarter valued at approximately $233,000. Sivia Capital Partners LLC raised its position in shares of McKesson by 77.9% during the 2nd quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock valued at $502,000 after buying an additional 300 shares during the period. Treasurer of the State of North Carolina grew its position in McKesson by 0.9% in the second quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company’s stock worth $42,958,000 after acquiring an additional 508 shares during the period. Finally, Osterweis Capital Management Inc. purchased a new position in McKesson in the second quarter worth approximately $166,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Quarterly results exceeded expectations. McKesson reported adjusted earnings of $9.93 per share, ahead of the $9.44-$9.56 analyst consensus range, while revenue rose 7.7% year over year to $105.38 billion, topping estimates. EPS also increased from $8.26 in the prior-year quarter. McKesson Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Specialty pharmaceutical growth drove profitability. Pharma profit rose 19%, supported by specialty medicine demand and oncology growth. Management raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, broadly in line with or above current analyst expectations. MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
• Positive Sentiment: Capital returns are becoming more attractive. McKesson plans approximately $5 billion in share repurchases and raised its dividend by 15%, potentially supporting per-share earnings and investor sentiment. McKesson Outlines Fiscal 2027 EPS and Share Repurchases
• Neutral Sentiment: McKesson is rebranding its Medical-Surgical Solutions business as Wellverse ahead of a planned spinoff and potential IPO. The move could unlock value, although it also introduces execution and separation risks. McKesson Debuts Wellverse Name
• Neutral Sentiment: Recent Zacks commentary characterizes MCK as a growth stock, citing earnings growth, specialty-drug exposure and improving fundamentals. However, these articles are analytical opinions rather than new company announcements. McKesson Is an Incredible Growth Stock

Wall Street Analyst Weigh In

A number of equities research analysts have commented on MCK shares. Citigroup lifted their target price on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Robert W. Baird set a $1,015.00 price target on McKesson in a report on Thursday. Wells Fargo & Company reduced their price objective on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Wall Street Zen cut shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Evercore reiterated an “outperform” rating on shares of McKesson in a research report on Thursday. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $968.93.

Insider Buying and Selling

In other McKesson news, EVP Thomas L. Rodgers sold 699 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total transaction of $513,953.73. Following the sale, the executive vice president owned 2,268 shares in the company, valued at $1,667,592.36. This represents a 23.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brian S. Tyler sold 8,463 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total value of $6,715,898.28. Following the completion of the sale, the chief executive officer directly owned 5,919 shares in the company, valued at $4,697,081.64. This represents a 58.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 28,748 shares of company stock worth $22,262,035 over the last ninety days. Insiders own 0.06% of the company’s stock.

McKesson Price Performance

Shares of NYSE:MCK opened at $871.72 on Friday. The firm has a market capitalization of $101.63 billion, a PE ratio of 23.33, a price-to-earnings-growth ratio of 1.43 and a beta of 0.30. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00. The firm’s 50-day moving average is $800.68 and its two-hundred day moving average is $840.98.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, beating the consensus estimate of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The business had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. During the same quarter last year, the firm posted $8.26 earnings per share. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Analysts expect that McKesson Corporation will post 44.59 EPS for the current fiscal year.

McKesson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be given a dividend of $0.94 per share. This is an increase from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 1st. McKesson’s dividend payout ratio is currently 10.06%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.